UCB (OTCMKTS:UCBJF) Stock Price Down 4.2% - Should You Sell?

Key Points

• UCB SA's stock price decreased by 4.2%, trading at $293.25, alongside a significant drop in trading volume of approximately 84% compared to its average daily volume.
• Despite the current downturn, analysts from Morgan Stanley and Deutsche Bank have maintained a Buy rating on UCB, suggesting confidence in the company's value.
• UCB specializes in biopharmaceuticals for neurology and immunology diseases, with key products including Cimzia for inflammatory diseases and several treatments for epilepsy.

UCB SA (OTCMKTS:UCBJF - Get Free Report)'s stock price was down 4.2% during mid-day trading on Thursday . The company traded as low as $293.25 and last traded at $293.25. Approximately 192 shares traded hands during trading, a decline of 84% from the average daily volume of 1,187 shares. The stock had previously closed at $306.09.

Analysts Set New Price Targets

Several research analysts recently commented on UCBJF shares. Morgan Stanley reaffirmed an "overweight" rating on shares of UCB in a research report on Monday, September 8th. Deutsche Bank Aktiengesellschaft reissued a "buy" rating on shares of UCB in a research note on Monday. Two research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of "Buy".

UCB Stock Down 6.6%

The firm's 50 day moving average price is $245.79 and its two-hundred day moving average price is $202.88. The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33.

About UCB

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.